The Day In Review: Biotech Manages A Gain, Though A Small One

March 7, 2005 After trading significantly higher for most of the day, the Centient Biotech 200 gave up most of the gains during the final few hours, though it managed to stay positive on the day. At the closing bell, the CBT 200 was up 2.55 points at 3199.98, a gain of .08%. We discuss the significant news of the day, including positive results for Revlimid from Celgene, a dead-cat bounce for Elan, disastrous data for Cell Therapeutics, a draw in the stent wars between Boston Scientific and Johnson and Johnson, and good news from the lab for Peregrine Pharma and its cancer drug...

Back to news